Congress wants FDA updates on drug safety changes
Congress' FY 2005 omnibus spending bill (HR 4818) conference report chastises FDA for failing to promptly provide documents related to drug safety activities to House and Senate Appropriations Committees. "The conferees find it necessary to remind" FDA "that the committees on Appropriations perform critical oversight functions for the agency," the report states. "It is insupportable that in some cases FDA has given information about major policy matters to the press before providing the same information to Congress." The conferees request "regular progress reports" on the Institute of Medicine's review of FDA's post-marketing safety regulatory system (1"The Pink Sheet" Nov. 15, 2004, p. 8)...
You may also be interested in...
FDA's decision to proceed with an Institute of Medicine review of drug safety regulation could trigger a full-fledged debate over the possibility of creating a separate post-marketing regulatory agency in the U.S
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.